#begin document (nw/p2.5_c2e/00/p2.5_c2e_0073); part 000
nw/p2.5_c2e/00/p2.5_c2e_0073   0    0     Xinhua     NNP  (TOP(FRAG(NP*   -   -   -   -   *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    1       News     NNP              *   -   -   -   -   *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    2     Agency     NNP              *)  -   -   -   -   *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    3    BEIJING     NNP           (NP*)  -   -   -   -   *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    4          ,       ,              *   -   -   -   -   *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    5       Dec.     NNP           (NP*   -   -   -   -   *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    6         5       CD              *)  -   -   -   -   *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    7     -LRB-   -LRB-               *   -   -   -   -   *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    8       Peng     NNP           (NP*   -   -   -   -   *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    9       Ting     NNP              *)  -   -   -   -   *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   10     -RRB-   -RRB-              *))  -   -   -   -   *   -

nw/p2.5_c2e/00/p2.5_c2e_0073   0   0              The    DT  (TOP(S(NP*    -    -   -   -   *   (ARG1*   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   1            fifth    NN           *)   -    -   -   -   *        *)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   2               is   VBZ        (VP*    be  01   2   -   *      (V*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   3              the    DT        (NP*    -    -   -   -   *   (ARG2*   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   4    International   NNP           *    -    -   -   -   *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   5        Volunteer   NNP           *    -    -   -   -   *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   6              Day   NNP          *))   -    -   -   -   *        *)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   7                .     .          *))   -    -   -   -   *        *   -

nw/p2.5_c2e/00/p2.5_c2e_0073   0    0            The     DT  (TOP(S(NP(NP*           -    -   -   -   *        (ARG1*   (ARG0*   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    1      Volunteer    NNP              *           -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    2           Team    NNP              *)          -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    3             of     IN           (PP*           -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    4            the     DT           (NP*           -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    5        Beijing    NNP              *           -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    6      Narcotics    NNP          (NML*           -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    7        Control    NNP              *)          -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    8    Association    NNP            *)))          -    -   -   -   *             *)       *)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    9            has    VBZ        (VP(VP*           -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   10     officially     RB         (ADVP*)          -    -   -   -   *    (ARGM-MNR*)       *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   11           been    VBN           (VP*           -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   12    established    VBN         (VP*)))   establish  01   -   -   *           (V*)       *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   13            and     CC              *           -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   14            has    VBZ           (VP*           -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   15          begun    VBN           (VP*        begin  01   2   -   *             *      (V*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   16              a     DT        (NP(NP*           -    -   -   -   *             *   (ARG1*   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   17           full     JJ          (NML*           -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   18             -    HYPH              *           -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   19          scale     NN              *)          -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   20    recruitment     NN              *)          -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   21             of     IN           (PP*           -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   22           drug     NN       (NP(NML*           -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   23        control     NN              *)          -    -   -   -   *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   24     volunteers    NNS         *))))))          -    -   -   -   *             *        *)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   25              .      .             *))          -    -   -   -   *             *        *   -

nw/p2.5_c2e/00/p2.5_c2e_0073   0    0              Liu    NNP  (TOP(S(NP(NP*               -    -   -   -   *   (ARG0*        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    1              Jie    NNP              *)              -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    2                ,      ,              *               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    3              the     DT        (NP(NP*               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    4             head     NN              *)              -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    5               of     IN           (PP*               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    6              the     DT        (NP(NP*               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    7        Volunteer    NNP              *               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    8             Team    NNP              *)              -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    9               of     IN           (PP*               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   10              the     DT           (NP*               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   11          Beijing    NNP              *               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   12        Narcotics    NNP          (NML*               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   13          Control    NNP              *)              -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   14      Association    NNP         *))))))              -    -   -   -   *        *)       *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   15                ,      ,              *               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   16             said    VBD           (VP*              say  01   1   -   *      (V*)       *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   17             that     IN         (SBAR*               -    -   -   -   *   (ARG1*        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   18              the     DT      (S(NP(NP*               -    -   -   -   *        *   (ARG2*        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   19             work     NN              *)              -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   20               of     IN           (PP*               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   21             drug     NN       (NP(NML*               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   22          control     NN              *)              -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   23       volunteers    NNS            *)))              -    -   -   -   *        *        *)       *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   24         includes    VBZ           (VP*          include  01   1   -   *        *      (V*)       *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   25    disseminating    VBG      (NP(S(VP*      disseminate  01   -   -   *        *   (ARG1*      (V*)        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   26        knowledge     NN        (NP(NP*)              -    -   -   -   *        *        *   (ARG1*         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   27               on     IN           (PP*               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   28             drug     NN           (NP*               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   29       prevention     NN          *)))))              -    -   -   -   *        *        *        *)        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   30                ,      ,              *               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   31          therapy     NN        (NP(NP*               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   32              and     CC              *               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   33       counseling     NN              *)         counsel   -   3   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   34              for     IN           (PP*               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   35             drug     NN           (NP*               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   36          addicts    NNS            *)))              -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   37                ,      ,              *               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   38    participation     NN        (NP(NP*)   participation   -   1   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   39               in     IN           (PP*               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   40             drug     NN      (NP(ADJP*               -    -   -   -   *        *        *        *    (ARG2*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   41               -    HYPH              *               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   42          related    VBN              *)          relate  01   -   -   *        *        *        *       (V*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   43          studies    NNS            *)))              -    -   -   -   *        *        *        *    (ARG1*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   44              and     CC              *               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   45               so     RB         (ADVP*               -    -   -   -   *        *        *        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   46               on     RB         *))))))              -    -   -   -   *        *)       *)       *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   47                .      .             *))              -    -   -   -   *        *        *        *         *   -

nw/p2.5_c2e/00/p2.5_c2e_0073   0    0            For     IN   (TOP(S(PP*             -    -   -   -   *    (ARGM-TMP*         *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    1            the     DT         (NP*             -    -   -   -   *             *         *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    2          first     JJ            *             -    -   -   -   *             *         *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    3           time     NN           *))            -    -   -   -   *             *)        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    4              ,      ,            *             -    -   -   -   *             *         *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    5     volunteers    NNS         (NP*)            -    -   -   -   *        (ARG2*)   (ARG0*)        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    6           will     MD         (VP*             -    -   -   -   *    (ARGM-MOD*)        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    7             be     VB         (VP*             -    -   -   -   *             *         *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    8      permitted    VBN         (VP*         permit  01   -   -   *           (V*)        *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    9             to     TO       (S(VP*             -    -   -   -   *        (ARG1*         *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   10    participate     VB         (VP*    participate  01   -   -   *             *       (V*)        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   11             in     IN         (PP*             -    -   -   -   *             *    (ARG1*         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   12           work     NN      (NP(NP*)            -    -   -   -   *             *         *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   13             on     IN         (PP*             -    -   -   -   *             *         *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   14           drug     NN    (NP(ADJP*             -    -   -   -   *             *         *    (ARG2*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   15             -    HYPH            *             -    -   -   -   *             *         *         *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   16        related    VBN            *)        relate  01   -   -   *             *         *       (V*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   17        studies    NNS   *))))))))))            -    -   -   -   *             *)        *)   (ARG1*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   18              .      .           *))            -    -   -   -   *             *         *         *   -

nw/p2.5_c2e/00/p2.5_c2e_0073   0    0          During    IN  (TOP(S(PP*          -    -   -   -   *    (ARGM-TMP*   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    1     recruitment    NN       (NP*))         -    -   -   -   *             *)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    2               ,     ,           *          -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    3      volunteers   NNS     (NP(NP*          -    -   -   -   *        (ARG1*   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    4               '   POS           *)         -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    5             own    JJ           *          -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    6    professional    JJ      (ADJP*          -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    7             and    CC           *          -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    8       technical    JJ           *)         -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    9       strengths   NNS           *)         -    -   -   -   *             *)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   10            will    MD        (VP*          -    -   -   -   *    (ARGM-MOD*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   11              be    VB        (VP*          -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   12      considered   VBN        (VP*    consider  02   -   -   *           (V*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   13           along    RB   (PP(ADVP*)         -    -   -   -   *    (ARGM-MNR*   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   14            with    IN           *          -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   15           other    JJ        (NP*          -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   16         factors   NNS       *)))))         -    -   -   -   *             *)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   17               .     .          *))         -    -   -   -   *             *   -

nw/p2.5_c2e/00/p2.5_c2e_0073   0    0               To     TO  (TOP(S(S(VP*            -    -   -   -   *            *    (ARGM-PRP*        *    (ARGM-PRP*   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    1       strengthen     VB          (VP*    strengthen  01   1   -   *          (V*)            *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    2              the     DT       (NP(NP*            -    -   -   -   *       (ARG1*             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    3         personal     JJ         (NML*            -    -   -   -   *            *             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    4           safety     NN             *)           -    -   -   -   *            *             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    5       guarantees    NNS             *)           -    -   -   -   *            *             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    6               of     IN          (PP*            -    -   -   -   *            *             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    7       volunteers    NNS        (NP*)))           -    -   -   -   *            *)            *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    8           during     IN          (PP*            -    -   -   -   *   (ARGM-TMP*             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    9             drug     NN      (NP(NML*            -    -   -   -   *            *             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   10          control     NN             *)           -    -   -   -   *            *             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   11             work     NN         *)))))           -    -   -   -   *            *)            *)       *             *)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   12                ,      ,             *            -    -   -   -   *            *             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   13              the     DT       (NP(NP*            -    -   -   -   *            *        (ARG1*        *        (ARG0*   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   14            ranks    NNS             *)           -    -   -   -   *            *             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   15               of     IN          (PP*            -    -   -   -   *            *             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   16       volunteers    NNS        (NP*)))           -    -   -   -   *            *             *)       *             *)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   17             will     MD          (VP*            -    -   -   -   *            *    (ARGM-MOD*)       *    (ARGM-MOD*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   18          undergo     VB       (VP(VP*       undergo  01   -   -   *            *           (V*)       *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   19          special     JJ       (NP(NP*            -    -   -   -   *            *        (ARG2*   (ARG1*             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   20     professional     JJ             *            -    -   -   -   *            *             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   21         training     NN             *)           -    -   -   -   *            *             *        *)            *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   22            based    VBN          (VP*          base  02   -   -   *            *             *      (V*)            *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   23               on     IN          (PP*            -    -   -   -   *            *             *   (ARG2*             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   24            their   PRP$          (NP*            -    -   -   -   *            *             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   25       respective     JJ             *            -    -   -   -   *            *             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   26        positions    NNS         *)))))           -    -   -   -   *            *             *)       *)            *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   27              and     CC             *            -    -   -   -   *            *             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   28            adopt     VB          (VP*         adopt  01   1   -   *            *             *        *           (V*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   29              the     DT          (NP*            -    -   -   -   *            *             *        *        (ARG1*   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   30        necessary     JJ             *            -    -   -   -   *            *             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   31    precautionary     JJ         (UCP*            -    -   -   -   *            *             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   32              and     CC             *            -    -   -   -   *            *             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   33        safeguard     NN             *)           -    -   -   -   *            *             *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   34         measures    NNS          *))))           -    -   -   -   *            *             *        *             *)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   35                .      .            *))           -    -   -   -   *            *             *        *             *   -

nw/p2.5_c2e/00/p2.5_c2e_0073   0    0          The     DT  (TOP(S(NP*       -    -   -   -   *        (ARG0*   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    1         drug     NN       (NML*       -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    2           -    HYPH           *       -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    3      control     NN           *)      -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    4    volunteer     NN           *       -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    5         team     NN           *)      -    -   -   -   *             *)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    6         does    VBZ        (VP*       -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    7          not     RB           *       -    -   -   -   *    (ARGM-NEG*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    8        admit     VB        (VP*    admit  02   2   -   *           (V*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    9        those     DT     (NP(NP*)      -    -   -   -   *        (ARG1*   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   10         with     IN        (PP*       -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   11            a     DT        (NP*       -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   12         drug     NN       (NML*       -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   13           -    HYPH           *       -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   14        crime     NN           *)      -    -   -   -   *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   15       record     NN       *)))))      -    -   -   -   *             *)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   16            .      .          *))      -    -   -   -   *             *   -

nw/p2.5_c2e/00/p2.5_c2e_0073   0    0       Otherwise    RB   (TOP(S(ADVP*)            -    -   -   -   *           *           *           *             *    (ARGM-DIS*)     *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    1               ,     ,              *             -    -   -   -   *           *           *           *             *             *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    2             all    DT        (NP(NP*             -    -   -   -   *      (ARG0*      (ARG0*      (ARG1*             *        (ARG0*      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    3        citizens   NNS              *)            -    -   -   -   *           *)          *)          *)            *             *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    4             who    WP    (SBAR(WHNP*)            -    -   -   -   *    (R-ARG0*)   (R-ARG0*)   (R-ARG1*)       (ARG0*)            *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    5            have   VBP      (S(VP(VP*             -    -   -   -   *           *           *           *             *             *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    6         reached   VBN           (VP*          reach  01   1   -   *         (V*)          *           *             *             *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    7             the    DT        (NP(NP*             -    -   -   -   *      (ARG1*           *           *             *             *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    8             age    NN              *)            -    -   -   -   *           *           *           *             *             *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    9              of    IN           (PP*             -    -   -   -   *           *           *           *             *             *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   10        eighteen    CD       (NP*)))))            -    -   -   -   *           *)          *           *             *             *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   11               ,     ,              *             -    -   -   -   *           *           *           *             *             *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   12         possess   VBP           (VP*        possess  01   1   -   *           *         (V*)          *             *             *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   13       political    JJ           (NP*             -    -   -   -   *           *      (ARG1*           *             *             *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   14          rights   NNS             *))            -    -   -   -   *           *           *)          *             *             *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   15             and    CC              *             -    -   -   -   *           *           *           *             *             *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   16             are   VBP           (VP*             be  01   1   -   *           *           *         (V*)            *             *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   17         willing    JJ         (ADJP*             -    -   -   -   *           *           *      (ARG2*             *             *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   18              to    TO         (S(VP*             -    -   -   -   *           *           *           *             *             *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   19    volunteerily    RB         (ADVP*)            -    -   -   -   *           *           *           *    (ARGM-MNR*)            *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   20            join    VB           (VP*           join  01   2   -   *           *           *           *           (V*)            *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   21             the    DT           (NP*             -    -   -   -   *           *           *           *        (ARG1*             *      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   22            team    NN     *))))))))))            -    -   -   -   *           *           *           *)            *)            *)     *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   23             can    MD           (VP*             -    -   -   -   *           *           *           *             *    (ARGM-MOD*)     *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   24          submit    VB           (VP*         submit  01   2   -   *           *           *           *             *           (V*)     *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   25              an    DT           (NP*             -    -   -   -   *           *           *           *             *        (ARG1*      *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   26     application    NN            *)))   application  01   2   -   *           *           *           *             *             *)   (V*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   27               .     .             *))            -    -   -   -   *           *           *           *             *             *      *   -

nw/p2.5_c2e/00/p2.5_c2e_0073   0    0    Foreigners    NNS   (TOP(S(NP(NP(NP*)       -    -   -   -   *           *        (ARG1*   (ARG1*   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    1            in     IN               (PP*        -    -   -   -   *           *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    2       Beijing    NNP             (NP*)))       -    -   -   -   *           *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    3           and     CC                  *        -    -   -   -   *           *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    4        former     JJ            (NP(NP*        -    -   -   -   *      (ARG0*             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    5       addicts    NNS                  *)       -    -   -   -   *           *)            *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    6           who     WP        (SBAR(WHNP*)       -    -   -   -   *    (R-ARG0*)            *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    7          have    VBP             (S(VP*        -    -   -   -   *           *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    8        broken    VBN               (VP*     break  01   3   -   *         (V*)            *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    9         their   PRP$               (NP*        -    -   -   -   *      (ARG1*             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   10          drug     NN                  *        -    -   -   -   *           *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   11         habit     NN            *)))))))       -    -   -   -   *           *)            *)       *)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   12           are    VBP               (VP*        be  01   1   -   *           *           (V*)       *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   13          also     RB             (ADVP*)       -    -   -   -   *           *    (ARGM-ADV*)       *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   14     qualified     JJ             (ADJP*        -    -   -   -   *           *        (ARG2*        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   15            to     TO             (S(VP*        -    -   -   -   *           *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   16        become     VB               (VP*    become  01   1   -   *           *             *      (V*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   17          drug     NN           (NP(NML*        -    -   -   -   *           *             *   (ARG2*   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   18    prevention     NN                  *)       -    -   -   -   *           *             *        *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   19    volunteers    NNS             *))))))       -    -   -   -   *           *             *)       *)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   20             .      .                 *))       -    -   -   -   *           *             *        *   -

nw/p2.5_c2e/00/p2.5_c2e_0073   0    0            It    PRP   (TOP(S(NP(NP*))         -    -   -   -   *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    1            is    VBZ             (VP*          -    -   -   -   *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    2     estimated    VBN             (VP*    estimate  01   -   -   *      (V*)            *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    3          that     IN           (SBAR*          -    -   -   -   *   (ARG1*             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    4            by     IN           (S(PP*          -    -   -   -   *        *    (ARGM-TMP*   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    5           the     DT          (NP(NP*          -    -   -   -   *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    6        Spring    NNP                *          -    -   -   -   *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    7      Festival    NNP                *)         -    -   -   -   *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    8            of     IN             (PP*          -    -   -   -   *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0    9         2007      CD          (NP*))))         -    -   -   -   *        *             *)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   10             ,      ,                *          -    -   -   -   *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   11       Beijing    NNP             (NP*)         -    -   -   -   *        *        (ARG0*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   12         could     MD             (VP*          -    -   -   -   *        *    (ARGM-MOD*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   13       recruit     VB             (VP*     recruit  01   1   -   *        *           (V*)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   14            up     IN          (NP(QP*          -    -   -   -   *        *        (ARG1*   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   15            to     TO                *          -    -   -   -   *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   16         5000      CD                *)         -    -   -   -   *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   17          drug     NN            (NML*          -    -   -   -   *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   18            -    HYPH                *          -    -   -   -   *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   19       control     NN                *)         -    -   -   -   *        *             *   -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   20    volunteers    NNS          *)))))))         -    -   -   -   *        *)            *)  -
nw/p2.5_c2e/00/p2.5_c2e_0073   0   21             .      .               *))         -    -   -   -   *        *             *   -

#end document
